1. Home
  2. QLYS vs TGTX Comparison

QLYS vs TGTX Comparison

Compare QLYS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Qualys Inc.

QLYS

Qualys Inc.

HOLD

Current Price

$128.86

Market Cap

4.7B

Sector

Technology

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$31.32

Market Cap

5.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QLYS
TGTX
Founded
1999
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
5.0B
IPO Year
2012
1995

Fundamental Metrics

Financial Performance
Metric
QLYS
TGTX
Price
$128.86
$31.32
Analyst Decision
Hold
Strong Buy
Analyst Count
15
5
Target Price
$139.43
$51.60
AVG Volume (30 Days)
347.1K
2.4M
Earning Date
02-05-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
13.91
N/A
EPS
5.16
2.78
Revenue
$653,034,000.00
$531,898,000.00
Revenue This Year
$12.00
$87.88
Revenue Next Year
$7.68
$47.78
P/E Ratio
$24.97
$11.24
Revenue Growth
10.13
100.88
52 Week Low
$112.61
$25.28
52 Week High
$155.47
$46.48

Technical Indicators

Market Signals
Indicator
QLYS
TGTX
Relative Strength Index (RSI) 34.34 55.99
Support Level $131.00 $29.80
Resistance Level $134.30 $33.24
Average True Range (ATR) 3.53 1.66
MACD -0.08 0.33
Stochastic Oscillator 18.03 71.18

Price Performance

Historical Comparison
QLYS
TGTX

About QLYS Qualys Inc.

Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: